HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools Register Now!
Market News Stocks News ETF News Crypto News

Zevra Therapeutics

Contributing Author

Recent Articles by Zevra Therapeutics

Nov-20
Zevra Therapeutics, Inc. Announces CFO Transition ZVRA GlobeNewswire
Nov-05
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update ZVRA GlobeNewswire
Oct-29
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference ZVRA GlobeNewswire
Oct-27
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call ZVRA GlobeNewswire
Oct-06
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ZVRA GlobeNewswire
Sep-18
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA (arimoclomol) and OLPRUVA (sodium phenylbutyrate) ZVRA GlobeNewswire
Sep-04
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) ZVRA GlobeNewswire
Aug-28
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) ZVRA GlobeNewswire
Aug-26
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September ZVRA GlobeNewswire
Aug-12
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update ZVRA GlobeNewswire
Aug-06
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference ZVRA GlobeNewswire
Aug-04
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call ZVRA GlobeNewswire
Jul-28
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C ZVRA GlobeNewswire
Jul-18
Zevra Therapeutics Announces MIPLYFFA and OLPRUVA Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) ZVRA GlobeNewswire
Jul-16
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism ZVRA GlobeNewswire
Jul-11
Zevra Therapeutics Announces MIPLYFFA (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference ZVRA GlobeNewswire
May-29
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders ZVRA GlobeNewswire
May-21
All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees ZVRA GlobeNewswire
May-13
Zevra Reports First Quarter 2025 Financial Results and Corporate Update ZVRA GlobeNewswire
May-06
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call ZVRA GlobeNewswire
May-01
Zevra Therapeutics to Participate in the Citizens Life Science Conference ZVRA GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.